Zurányi Anna, Vasziné Szabó Enikő, Tóth Zsuzsanna
Konzerváló Fogászati Klinika, Semmelweis Egyetem, Fogorvostudományi Kar Budapest, Üllői út 26., 1085.
Orv Hetil. 2019 Feb;160(7):243-251. doi: 10.1556/650.2019.31204.
Medication-related osteonecrosis of the jaw may appear as adverse effect in antiresorptive therapy. Its successful treatment is challenging. We aimed to gather the systemic and local factors playing a role in etiology, published after its recognition. Risk factors were collected from the PubMed database 1998-2018. The three main groups of risk patients are: patients starting, patients having antiresorptive therapy, osteonecrosis diagnosed patients. The dentist must recognize risk factors, determine appropriate treatment plan and frequency of check-ups. Oncological disease treated intravenously means the greatest risk. Further systemic risk factors are: supportive therapies, concomitant disease, way of life, individual factors. Local risk factors may be: dentoalveolar surgery, periapical and periodontal inflammation, ill-fitting denture, presence of some anatomical structures. The accumulation of risk factors determines the probability of the manifestation of osteonecrosis. The most favorable case is patient starting antiresorptive therapy with a dental status needing no treatment. Orv hetil. 2019; 160(7): 243-251.
药物相关性颌骨坏死可能是抗吸收治疗的不良反应。其成功治疗具有挑战性。我们旨在收集自其被认识以来发表的、在病因学中起作用的全身和局部因素。从1998年至2018年的PubMed数据库中收集危险因素。主要的三类风险患者为:开始抗吸收治疗的患者、正在进行抗吸收治疗的患者、已诊断为骨坏死的患者。牙医必须识别危险因素,确定合适的治疗方案和检查频率。静脉内治疗的肿瘤疾病意味着最大风险。其他全身危险因素包括:支持性治疗、伴随疾病、生活方式、个体因素。局部危险因素可能有:牙槽外科手术、根尖周炎和牙周炎、义齿不合适、某些解剖结构的存在。危险因素的累积决定了骨坏死表现的可能性。最有利的情况是开始抗吸收治疗的患者,其口腔状况无需治疗。《匈牙利医学周报》2019年;160(7):243 - 251。